What are the side effects of Wayrilz (Rilzabrutinib)?

Wayrilz (Rilzabrutinib) has shown a range of side effects in clinical studies, with the most common adverse reactions (incidence ≥10%) including diarrhea, nausea, headache, abdominal pain, and COVID-19. The occurrence of these side effects may affect the patient's quality of life, so patients need to pay close attention to the body's reaction when using this drug.

In some cases, Wayrilz side effects may cause patients to stop taking the drug. Specifically, adverse reactions leading to discontinuation include erythema nodosum, neutropenia, joint pain, dyspepsia, headache, limb pain, abdominal discomfort, diarrhea, nausea, and pneumonia. The diversity of these responses reminds clinicians to conduct a comprehensive assessment of the patient's health status during treatment.

In addition, during the treatment of Wayrilz for the treatment of persistent or chronic immune thrombocytopenia (ITP), the study also identified some situations that require special vigilance, such as serious infections and hepatotoxicity, including drug-induced liver injury. At the same time, pregnant women need to pay attention to the issue of embryo-fetal toxicity. These warnings and precautions indicate that the use of Wayrilz must be conducted under the guidance of a doctor to ensure patient safety.

For patients who experience severe side effects, doctors may choose to discontinue the medication and reduce the dose as they recover, or, in more severe cases, consider permanently discontinuing treatment. This flexible adjustment strategy provides patients with safer treatment options and helps reduce the risk of side effects.

In short, althoughWayrilz provides new hope for the treatment of ITP, its side effects cannot be ignored. During use, patients should maintain good communication with their doctors and report their body's reactions in a timely manner so that corresponding adjustments and management can be made. Proper medication management can help maximize the therapeutic effect of Wayrilz while minimizing the impact of adverse reactions.

Reference materials:https://go.drugbank.com/drugs/DB17709